Table 2.
Chimeric antigen receptor T-cell (CAR-T) survival outcomes from pivotal clinical trials
| Commercial name | Drug name | Median OS, months | Median PFS, months | Median follow-up, months | CR | PR | References |
|---|---|---|---|---|---|---|---|
| Kymriah | Tisagenlecleucel | 11.1 | 2.9 | 40.3 | 39% | 14% | [1] |
| Yescarta | Axicabtagene ciloleucel | 25.8 | 8.3 | 51.1 | 54% | 21% | [2] |
| Breyanzi | Lisocabtagene maraleucel | 27.3 | 6.8 | 17.7 | 54% | 19% | [35] |
| Tecartus | Brexucabtagene autoleucel |
MCL—15 ALL—18.2 |
MCL—9 ALL—11.6 |
MCL—12.3 ALL—22.1 |
MCL—67% ALL—52% |
MCL—25% ALL—n/a |
[36–38] |
| Abecma | Idecabtagene vicleucel | 22 | 8.6 | 24.8 | 33% | 20% | [18] |
OS overall survival, PFS progression-free survival, CR complete response, PR partial response, MCL mantle cell lymphoma, ALL acute lymphoblastic leukemia